OptimizeRx Corporation reports developments in healthcare technology for life sciences marketing, with updates centered on tools that connect pharmaceutical brands with healthcare professionals and patients. The company’s platform uses EHR-based access, omnichannel activation, the Dynamic Audience Activation Platform, and Micro-Neighborhood audiences to support HCP and direct-to-consumer engagement.
Recurring OptimizeRx news includes product and network launches, programmatic access to EHR advertising, privacy-safe identity resolution collaborations, quarterly and annual results, debt and share-repurchase actions, and board or leadership changes. Coverage also reflects the company’s focus on privacy-compliant audience targeting and campaign measurement across healthcare marketing channels.
OptimizeRx Corp. (OPRX) reported Q3 2022 revenue of $15.1 million, a 6% year-over-year decline but an 8% quarter-over-quarter increase. Gross profit rose 4% to $9.4 million, with gross margins improving from 56% to 62%. The company generated $7.9 million in cash flow from operations in the first nine months of 2022 and has repurchased 1.1 million shares at an average price of $16.70. The 2022 revenue outlook remains between $62 million and $68 million, indicating 1% to 11% growth.
OptimizeRx Corp (Nasdaq: OPRX) announced its third annual Innovate4Outcomes event, set for December 1, 2022. Co-sponsored with Melinta Therapeutics, this virtual event will bring together healthcare providers and industry professionals to tackle Antimicrobial Resistance (AMR), identified by the WHO as a major global health challenge. Participants will collaborate in teams to devise solutions, with the winning concept receiving support for further development. This initiative underscores the company’s commitment to enhancing therapy access and adherence amid pressing healthcare issues.
OptimizeRx Corp (Nasdaq: OPRX) announced a conference call scheduled for November 8, 2022, at 4:30 p.m. ET to discuss its third-quarter financial results for the period ended September 30, 2022. The call will be hosted by OptimizeRx management, followed by a question-and-answer session. Investors can access details via a webcast or through toll-free and international numbers. This call follows the release of the financial results, which will be issued beforehand.
OptimizeRx specializes in point-of-care technology solutions that facilitate patient therapy adherence.
OptimizeRx (Nasdaq: OPRX) has announced successful results from a program utilizing its AI/real-world evidence technology to improve patient identification for specialty therapy. The initiative showed a 28% increase in therapy initiation per healthcare provider and identified 33% of new patients accurately. Key features of the program included earlier patient identification and data-driven qualification, enhancing communication between healthcare providers and patients. This advancement aims to address challenges in misdiagnosis and treatment delays for complex diseases.
OptimizeRx Corp (Nasdaq: OPRX) has announced a renewed exclusive partnership with Therapy Brands, extending their collaboration that began in 2019. This agreement enhances the access to NewCrop's ePrescribing platform, which supports healthcare professionals (HCPs) through OptimizeRx's Therapy Initiation and Persistence Platform. Both companies aim to streamline workflows and improve patient treatment information accessibility. The partnership reinforces OptimizeRx's position in delivering point-of-care solutions that help patients start and maintain their therapy effectively.
OptimizeRx Corp (Nasdaq: OPRX) announced its participation in three upcoming conferences this September. Management will attend the R.W. Baird Healthcare Conference in New York City on September 13, the Lake Street BIG6 Investor Conference on September 14, and the LifeSci Health Tech Symposium virtually on September 21. Presentations will cover the company's innovative point-of-care technology solutions aimed at helping patients manage their therapies. Interested parties can request in-person meetings through designated contacts.
OptimizeRx Corp (Nasdaq: OPRX) reports a successful case study highlighting its patent-pending real-world evidence solution, which identifies healthcare providers (HCPs) with patients at risk of non-adherence due to unexpected costs. The program, launched with a major pharmaceutical manufacturer, achieved over 200% growth in identified HCPs, leading to more than 46,000 additional prescriptions. The solution demonstrated a +6:1 return on investment and helped 27% of targeted HCPs enroll new patients. This advancement in predictive analytics showcases the company's ability to improve patient care and support HCPs effectively.
OptimizeRx Corp. (Nasdaq: OPRX) reported a 3% increase in revenue for Q2 2022, totaling $14.0 million, compared to $13.6 million in Q2 2021, largely due to new customer and program launches. Gross profit rose 12% year-over-year to $9.0 million. However, the company experienced a GAAP net loss of $3.9 million or ($0.21 per share). Cash and cash equivalents increased to $87.4 million. The updated 2022 revenue outlook anticipates $62 million to $68 million, marking 1% to 11% growth from 2021.
OptimizeRx Corp. (Nasdaq: OPRX) reported a 3% revenue increase to $14.0 million for Q2 2022, driven by new customers and program launches. Gross profit rose 12% year-over-year to $9.0 million, with a gross margin of 64%. However, the company faced a GAAP net loss of $3.9 million, significantly down from a profit of $0.4 million in the same quarter last year. Full year revenue guidance is updated to $62-$68 million, reflecting anticipated industry challenges. Cash reserves totaled $87.4 million as of June 30.
OptimizeRx Corp. (Nasdaq: OPRX) has partnered with Cooler Screens to enhance healthcare advertising strategies through digital media platforms in retail pharmacies. This collaboration aims to boost patient engagement and improve access to affordable medications. Cooler Screens operates over 10,000 screens nationwide, reaching 90 million consumers monthly. The partnership enables agencies to utilize direct-to-consumer marketing strategies that enhance therapy adherence. The collaboration seeks to address the significant issue of medication affordability affecting 18 million Americans, highlighting the importance of accessible healthcare communication.